Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants

Oladunni, Fatai S.; Park, Jun-Gyu; Chiem, Kevin; Ye, Chengjin; Pipenbrink, Michael; Walter, Mark R.; Kobie, James J.; Martínez-Sobrido, Luis

doi:10.1016/j.jviromet.2021.114084

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, a recombinant protein barely reflects the spike protein's configuration on the virus and could be denatured during noncompliant storage. Most importantly, existing test systems to assay blocking antibodies should be quickly adaptable to escape mutants that appear to be more infectious and are suspected to worsen the disease [14,[28][29][30].…”

Section: Introductionmentioning

confidence: 99%

A surrogate cell‐based SARS‐CoV‐2 spike blocking assay

et al. 2021

View full text Add to dashboard Cite

To monitor infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and successful vaccination against coronavirus disease 2019 (COVID-19), the kinetics of neutralizing or blocking anti-SARS-CoV-2 antibody titers need to be assessed. Here, we report the development of a quick and inexpensive surrogate SARS-CoV-2 blocking assay (SUBA) using immobilized recombinant human angiotensin-converting enzyme 2 (hACE2) and human cells expressing the native form of surface SARS-CoV-2 spike protein. Spike protein-expressing cells bound to hACE2 in the absence or presence of blocking antibodies were quantified by measuring the optical density of cell-associated crystal violet in a spectrophotometer. The advantages are that SUBA is a fast and inexpensive assay, which does not require biosafety level 2-or 3-approved laboratories. Most importantly, SUBA detects blocking antibodies against the native trimeric cell-bound SARS-CoV-2 spike protein and can be rapidly adjusted to quickly pre-screen already approved therapeutic antibodies or sera from vaccinated individuals for their ACE2 blocking activities against any emerging SARS-CoV-2 variants.

show abstract

Section: Introductionmentioning

confidence: 99%